An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings.
Journal
Histology and histopathology
ISSN: 1699-5848
Titre abrégé: Histol Histopathol
Pays: Spain
ID NLM: 8609357
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
24
9
2020
medline:
14
10
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
Although osteosarcoma is a rare disease, with a global incidence rate estimated at 5.0/million/year, it is the most frequent primary bone sarcoma in children and adolescents. In translational research, the patient-derived xenograft (PDX) model is considered an authentic in vivo model for several types of cancer, as tumorgrafts faithfully retain the biological characteristics of the primary tumors. Our goal was to investigate the association between PDX formation and clinical findings of osteosarcoma patients and the ability of the model to preserve in immunocompromized mice the characteristics of the parental tumor. A fresh sample of the patient tumor obtained from a representative biopsy or from surgical resection was implanted into nude mice. When tumor outgrowths reached ~1,500mm³, fresh PDX fragments were re-transplanted into new hosts. Engraftment in mice was obtained after a latency period of 19-225 days (median 92 days) in 40.54% of the implanted samples. We confirmed the histopathological fidelity between the patient tumor and their respective established PDXs, including the expression of biomarkers. PDX take rate was higher in surgical resection samples, in post-chemotherapy surgical samples and in samples from patients with metastatic disease at presentation. In conclusion, we have shown that the osteosarcoma PDX model reliably recapitulates the morphological aspects of the human disease after serial passage in mice. The observation that more aggressive forms of osteosarcoma, including those with metastatic disease at presentation, have a higher efficiency to generate PDXs provides a promising scenario to address several unanswered issues in clinical oncology.
Identifiants
pubmed: 32964941
pii: HH-18-256
doi: 10.14670/HH-18-256
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1295-1307Subventions
Organisme : -
ID : -
Références
Ben-David U., Ha G., Tseng Y., Greenwald N.F., Oh C., Shih J., McFarland J.M., Wong B., Boehm J.S., Beroukhim R. and Golub T.R. (2017). Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567-1575.
pmcid: PMC5659952
pubmed: 28991255
Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., Zoubek A., Jürgens H. and Winkler K. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20, 776-790.
pubmed: 11821461
Blattmann C., Thiemann M., Stenzinger A., Roth E.K., Dittmar A., Witt H., Lehner B., Renker E., Jugold M., Eichwald V., Weichert W., Huber P.E. and Kulozik P.E. (2015). Establishment of a patientderived orthotopic osteosarcoma mouse model. J. Transl. Med. 13, 136.
pmcid: PMC4428092
pubmed: 25926029
Bruheim S., Bruland O.S., Breistol K., Maelandsmo G.M. and Fodstad O. (2004). Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol. Oncol. Res. 10, 133-141.
pubmed: 15448748
Cornillie J., Wozniak A., Li H., Wang Y., Boeckx B., Gebreyohannes Y.K., Wellens J., Vanleeuw U., Hompes D., Stas M., Sinnaeve F., Wafa H., Lambrechts D., Debiec-Rychter M., Sciot R. and Schöffski P. (2019). Establishment and characterization of histologically and molecularly stable soft tissue sarcoma xenograft models for biological studies and preclinical drug testing. Mol. Cancer Ther. 18, 1168-1178.
pubmed: 30962320
Crnalic S., Hakansson I., Boquist L., Lofvenberg R. and Brostrom L.A. (1997). A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin. Exp. Metastasis 15, 164- 172.
pubmed: 9062393
Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D. and Watkins D.N. (2009). A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69, 3364-3373.
pmcid: PMC2821899
pubmed: 19351829
De Rose Y.S., Wang G., Lin Y., Bernard P.S., Buys S.S., Ebbert M.T.W, Factor R., Matsen C., Milash B.A., Nelson E., Neumayer L., Randall R.L., Stijleman I.J., Welm B.E. and Welm A.L. (2013). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520.
pmcid: PMC3553601
pubmed: 22019887
Depreeuw J., Hermans E., Schrauwen S., Annibali D., Coenegrachts L., Thomas D., Luyckx M., Gutierrez-Roelens I., Debruyne D., Konings K., Moerman P., Vergote I., Lambrechts D. and Amant F. (2015). Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol. Oncol. 139, 118-126.
pubmed: 26232337
Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., Abbott R.M., Hoog J., Dooling D.J., Koboldt D.C., Schmidt H., Kalicki J., Zhang Q., Chen L., Lin L., Wendl M.C., McMichael J.F., Magrini V.J., Cook L., McGrath S.D., Vickery T.L., Appelbaum E., Deschryver K., Davies S., Guintoli T., Lin L., Crowder R., Tao Y., Snider J.E., Smith S.M., Dukes A.F., Sanderson G.E., Pohl C.S., Delehaunty K.D., Fronick C.C., Pape K.A., Reed J.S., Robinson J.S., Hodges J.S., Schierding W., Dees N.D., Shen D., Locke D.P., Wiechert M.E., Eldred J.M., Peck J.B., Oberkfell B.J., Lolofie J.T., Du F., Hawkins A.E., O'Laughlin M.D., Bernard K.E., Cunningham M., Elliott G., Mason M.D., Thompson D.M. Jr., Ivanovich J.L., Goodfellow P.J., Perou C.M., Weinstock G.M., Aft R., Watson M., Ley T.J., Wilson R.K. and Mardis E.R. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005.
pmcid: PMC2872544
pubmed: 20393555
Garber K. (2009). From human to mouse and back: "Tumorgraft'' models surge in popularity. J. Natl. Cancer Inst. 101, 6-8.
pubmed: 19116380
Garrido-Laguna I., Uson M., Rajeshkumar N.V., Tan A.C., de Oliveira E., Karikari C., Villaroel M.C., Salomon A., Taylor G., Sharma R., Hruban R.H., Maitra A., Laheru D., Rubio-Viqueira B., Jimeno A. and Hidalgo M. (2011). Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793-5800
pmcid: PMC3210576
pubmed: 21742805
Isakoff M.S., Bielack S.S., Meltzer P. and Gorlick R. (2015). Osteosarcoma: current treatment and a collaborative pathway to success. J. Clin. Oncol. 33, 3029-3035.
pmcid: PMC4979196
pubmed: 26304877
Izumchenko E., Paz K., Ciznadija D., Sloma I., Katz A., VasquezDunddel D., Ben-Zvi I., Stebbing J., McGuire W., Harris W., Maki R., Gaya A., Bedi A., Zacharoulis S., Ravi R., Wexler L.H., Hoque M.O., Rodriguez-Galindo C., Pass H., Peled N., Davies A., Morris R., Hidalgo M. and Sidransky D. (2017). Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595-2605
pmcid: PMC5834154
pubmed: 28945830
Jawad M.U. and Scully S.P. (2010). In brief: Classifications in brief: Enneking classification: benign and malignant tumors of the musculoskeletal system. Clin. Orthop. Rel. Res. 468, 2000-2002.
pmcid: PMC2882012
pubmed: 20333492
John T., Kohler D., Pintilie M., Yanagawa N., Pham N.A., Li M., Panchal D., Hui F., Meng F., Shepherd F.A. and Tsao M.S. (2011). The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res. 17, 134-141.
pubmed: 21081655
Joshua B., Kaplan M.J., Doweck I., Pai R., Weissman I.L., Prince M.E. and Ailles L.E. (2012). Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck 34, 42-49.
pubmed: 21322081
Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goéré D., Mariani P., Landron S., Bigot L., Nemati F., Dartigues P., Weiswald L.B., Lantuas D., Morgand L., Pham E., Gonin P., Dangles-Marie V., Job B., Dessen P., Bruno A., Pierré A., De Thé H., Soliman H., Nunes M., Lardier G., Calvet L., Demers B., Prévost G., Vrignaud P., Roman-Roman S., Duchamp O. and Berthet C. (2012). Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314-5328.
pubmed: 22825584
Kim M.P., Evans D.B., Wang H., Abbruzzese J.L., Fleming J.B. and Gallick G.E. (2009). Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protoc. 4, 1670-1680.
pmcid: PMC4203372
pubmed: 19876027
Kresse S.H., Meza-Zepeda L.A., Machado I., Llombart-Bosch A. and Myklebost O. (2012). Preclinical xenograft models of human sarcomas show nonrandom loss of aberrations. Cancer 118, 558- 570.
pubmed: 21713766
Langdon S.P. (2012). Animal modeling of cancer pathology and studying tumor response to therapy. Curr. Drug Targets 13, 1535- 1547.
pubmed: 22974396
Lu W., Chao T., Ruiqi C., Juan S. and Zhihong L. (2018). Patientderived xenograft models in musculoskeletal malignancies. J. Transl. Med. 16, 107.
pmcid: PMC5913806
pubmed: 29688859
Martin J.W., Squire J.A. and Zielenska M. (2012). The genetics of osteosarcoma. Sarcoma 2012, 627254.
pmcid: PMC3364016
pubmed: 22685381
McAuliffe P.F., Evans K.W., Akcakanat A., Chen K., Zheng X., Zhao H., Eterovic A.K., Sangai T., Holder A.M., Sharma C., Chen H., Do K.A., Tarco E., Gagea M., Naff K.A., Sahin A., Multani A.S., Black D.M., Mittendorf E.A., Bedrosian I., Mills G.B., Gonzalez-Angulo A.M. and Meric-Bernstam F. (2015). Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One 10, e0136851.
pmcid: PMC4556673
pubmed: 26325287
Meohas W., Granato R.A., Guimarães J.A.M., Dias R.B., Fortuna-Costa A. and Duarte M.E.L. (2018). Patient-derived xenografts as a preclinical model for bone sarcomas. Acta Ortop. Bras. 26, 98- 102.
pmcid: PMC6032614
pubmed: 29983625
Mirabello L., Troisi R.J. and Savage S.A. (2009a). International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int. J. Cancer 125, 229-234.
pmcid: PMC3048853
pubmed: 19330840
Mirabello L., Troisi R.J. and Savage S.A. (2009b). Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531-1543
pmcid: PMC2813207
pubmed: 19197972
Mirabello L., Zhu B., Koster R., Karlins E., Dean M., Yeager M., Gianferante M., Spector L.G., Morton L.M., Karyadi D., Robison L.L., Armstrong G.T., Bhatia S., Song L., Pankratz N., Pinheiro M., Gastier-Foster J.M., Gorlick R., de Toledo S.R.C., Petrilli A.S., Patino-Garcia A., Lecanda F., Gutierrez-Jimeno M., Serra M., Hattinger C., Picci P., Scotlandi K., Flanagan A.M., Tirabosco R., Amary M.F., Kurucu N., Ilhan I.E., Ballinger M.L., Thomas D.M., Barkauskas D.A., Mejia-Baltodano G., Valverde P., Hicks B.D., Zhu B., Wang M., Hutchinson A.A., Tucker M., Sampson J., Landi M.T., Freedman N.D., Gapstur S., Carter B., Hoover R.N., Chanock S.J. and Savage S.A. (2020). Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 6, 724-734
pmcid: PMC7082769
pubmed: 32191290
Monsma D.J., Monks N.R., Cherba D.M., Dylewski D., Eugster E., Jahn H., Srikanth S., Scott S.B., Richardson P.J., Everts R.E., Ishkin A., Nikolsky Y., Resau J.H., Sigler R., Nickoloff B.J. and Webb C.P. (2012). Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J. Transl. Med. 10, 125.
pmcid: PMC3439334
pubmed: 22709571
Nanni P., Landuzzi L., Manara M.C., Righi A., Nicoletti G., Cristalli C., Pasello M., Parra A., Carrabotta M., Ferracin M., Palladini A., Ianzano M.L., Giusti V., Ruzzi F., Magnani M., Donati D.M., Picci P., Lollini P.L. and Scotlandi K. (2019). Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Sci. Rep. 9, 12174.
pmcid: PMC6704066
pubmed: 31434953
Pergolini I., Morales-Oyarvide V., Mino-Kenudson M., Honselmann K.C., Rosenbaum M.W., Nahar S., Kem M., Ferrone C.R., Lillemoe K.D., Bardeesy N., Ryan D.P., Thayer S.P., Warshaw A.L., Fernández-Del Castillo C. and Liss A.S. (2017). Tumor engraftment in patientderived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One 12, e0182855.
pmcid: PMC5576681
pubmed: 28854237
Press J.Z., Kenyon J.A., Xue H., Miller M.A., De Luca A., Miller D.M., Huntsman D.G., Gilks C.B., McAlpine J.N. and Wang Y.Z. (2008). Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 110, 256-264.
pubmed: 18547621
Rainusso N., Cleveland H., Hernandez J.A., Quintanilla N.M., Hicks J., Vasudevan S., Marco R.A.W., Allen-Rhoades W., Wang L.L. and Yustein J.T. (2018). Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. Pediatr. Blood Cancer 66, e27579.
pubmed: 30548185
Ricci F., Bizzaro F., Cesca M., Guffanti F., Ganzinelli M., Decio A., Ghilardi C., Perego P., Fruscio R., Buda A., Milani R., Ostano P., Chiorino G., Bani M.R., Damia G. and Giavazzi R. (2014). Patientderived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 74, 6980- 6990.
pubmed: 25304260
Siolas D. and Hannon G.J. (2013). Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315-5319
pmcid: PMC3766500
pubmed: 23733750
Stewart E., Federico S.M., Chen X., Shelat A.A., Bradley C., Gordon B., Karlstrom A., Twaroq N.R., Clay M.R., Bahrami A., Freeman B.B. 3rd., Xu B., Zhou X., Wu J., Honnell V., Ocarz M., Blankenship K., Dapper J., Mardis E.R., Wilson R.K., Downing J., Zhang J., Easton J., Pappo A. and Dyer M.A. (2017). Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96-100.
pmcid: PMC5659286
pubmed: 28854174
Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A. and Eckhardt S.G. (2012). Patientderived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350.
pmcid: PMC3928688
pubmed: 22508028
Zhang X., Zhang J., Li M., Huang X., Yang X., Zhong W., Xie L., Zhang L., Zhou M., Gavine P., Su X., Zheng L., Zhu G., Zhan P., Ji Q. and Wu Y.L. (2013). Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR-1: useful tools for preclinical studies of targeted therapies. J. Transl. Med. 11, 168.
pmcid: PMC3716998
pubmed: 23842453
Zhang T., Li J., Yin F., Bin B., Wang Z., Xu J., Wang H., Zuo D., Wang G., Hua Y. and Cai Z. (2017). Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT 3. Oncogene 36, 6627-6639.
pmcid: PMC5702716
pubmed: 28783167